665 related articles for article (PubMed ID: 29133133)
21. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
Matosevic S
J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
[TBL] [Abstract][Full Text] [Related]
22. A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.
Yang H; Tang R; Li J; Liu Y; Ye L; Shao D; Jin M; Huang Q; Shi J
Cell Biochem Biophys; 2015 Dec; 73(3):723-9. PubMed ID: 27259316
[TBL] [Abstract][Full Text] [Related]
23. Natural killer cell receptors: alterations and therapeutic targeting in malignancies.
Konjević G; Vuletić A; Mirjačić Martinović K
Immunol Res; 2016 Feb; 64(1):25-35. PubMed ID: 26374324
[TBL] [Abstract][Full Text] [Related]
24. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
25. Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer.
Davis ZB; Felices M; Verneris MR; Miller JS
Cancer J; 2015; 21(6):486-91. PubMed ID: 26588681
[TBL] [Abstract][Full Text] [Related]
26. NK cell-based immunotherapy for cancer.
Fang F; Xiao W; Tian Z
Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
[TBL] [Abstract][Full Text] [Related]
27. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.
Tonn T; Becker S; Esser R; Schwabe D; Seifried E
J Hematother Stem Cell Res; 2001 Aug; 10(4):535-44. PubMed ID: 11522236
[TBL] [Abstract][Full Text] [Related]
28. Improving natural killer cell cancer immunotherapy.
Berrien-Elliott MM; Romee R; Fehniger TA
Curr Opin Organ Transplant; 2015 Dec; 20(6):671-80. PubMed ID: 26414502
[TBL] [Abstract][Full Text] [Related]
29. Leveraging natural killer cells for cancer immunotherapy.
Grossenbacher SK; Aguilar EG; Murphy WJ
Immunotherapy; 2017 May; 9(6):487-497. PubMed ID: 28472904
[TBL] [Abstract][Full Text] [Related]
30. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Ben-Shmuel A; Biber G; Barda-Saad M
Front Immunol; 2020; 11():275. PubMed ID: 32153582
[TBL] [Abstract][Full Text] [Related]
31. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer.
Arina A; Murillo O; Dubrot J; Azpilikueta A; Alfaro C; Pérez-Gracia JL; Bendandi M; Palencia B; Hervás-Stubbs S; Melero I
Expert Opin Biol Ther; 2007 May; 7(5):599-615. PubMed ID: 17477799
[TBL] [Abstract][Full Text] [Related]
32. Possible damage to immune-privileged sites in natural killer cell therapy in cancer patients: side effects of natural killer cell therapy.
Bolourian A; Mojtahedi Z
Immunotherapy; 2017 Mar; 9(3):281-288. PubMed ID: 28231718
[TBL] [Abstract][Full Text] [Related]
33. Natural Killer Cell-Based Cancer Immunotherapy: A Review on 10 Years Completed Clinical Trials.
Suen WC; Lee WY; Leung KT; Pan XH; Li G
Cancer Invest; 2018; 36(8):431-457. PubMed ID: 30325244
[TBL] [Abstract][Full Text] [Related]
34. Natural Killer Cells: Angels and Devils for Immunotherapy.
Martín-Antonio B; Suñe G; Perez-Amill L; Castella M; Urbano-Ispizua A
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28850071
[TBL] [Abstract][Full Text] [Related]
35. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
36. Human NK cells: From surface receptors to clinical applications.
Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
[TBL] [Abstract][Full Text] [Related]
37. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.
Kozlowska AK; Kaur K; Topchyan P; Jewett A
Cancer Immunol Immunother; 2016 Jul; 65(7):835-45. PubMed ID: 27034236
[TBL] [Abstract][Full Text] [Related]
38. Bench to bedside: NK cells and control of metastasis.
Krasnova Y; Putz EM; Smyth MJ; Souza-Fonseca-Guimaraes F
Clin Immunol; 2017 Apr; 177():50-59. PubMed ID: 26476139
[TBL] [Abstract][Full Text] [Related]
39. NK cells to cure cancer.
Di Vito C; Mikulak J; Zaghi E; Pesce S; Marcenaro E; Mavilio D
Semin Immunol; 2019 Feb; 41():101272. PubMed ID: 31085114
[TBL] [Abstract][Full Text] [Related]
40. Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer.
Obajdin J; Davies DM; Maher J
Clin Exp Immunol; 2020 Oct; 202(1):11-27. PubMed ID: 32544282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]